The global AI-powered diagnostic radiogenomics devices market size was valued at USD 990 million in 2024 and is expected to reach USD 4,089.49 million by 2032, at a CAGR of 19.40% during the forecast period
The market growth is largely fueled by the integration of artificial intelligence with advanced medical imaging and genomic profiling, enabling more precise, non-invasive, and personalized diagnostic solutions in oncology and other disease areas
Furthermore, rising demand for precision medicine, early disease detection, and AI-driven decision support in hospitals and research centers is positioning radiogenomics as a transformative diagnostic technology. These converging factors are accelerating adoption across healthcare systems, thereby significantly boosting the industry’s growth